^
    Back
    Association details:
    Biomarker:NRAS mutation
    Cancer:Colorectal Cancer
    Drug:Estybon (rigosertib) (PI3K inhibitor, PLK1 inhibitor, RAS antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR-II 2020
    Title:

    Translational research of rigosertib, a small molecule RAS-mimetic for the treatment of RAS mutant colorectal cancer

    Published date:
    05/15/2020
    Excerpt:
    Preliminary analysis of this study showed that RGS has a definite inhibitory effect on RAS mutant colorectal cancer via inhibiting cell proliferation & inducing endogenous apoptosis.